Skip to content

On June 19, 2012, AstraZeneca PLC completed its acquisition of Ardea Biosciences, Inc. Upon completion of the merger, Ardea became a wholly owned subsidiary of AstraZeneca. The total transaction value was approximately $1.26 billion. See Ardea's public filings with the Securities and Exchange Commission for more information.